Stockscreener 앱 받기
3.00
3.54%
-0.11
시간 외 거래:
3.00
전일 마감가:
$3.11
열려 있는:
$3.1
하루 거래량:
176.20K
Relative Volume:
0.47
시가총액:
$130.81M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-7.41%
1개월 성능:
-22.28%
6개월 성능:
-57.02%
1년 성능:
+0.00%
1일 변동 폭
$3.00
$3.11
1주일 범위
$3.00
$3.40
52주 변동 폭
$3.00
$30.60
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
3.00 | 130.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewswire Inc.
KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors - The Bakersfield Californian
Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
Kyverna Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesKYTX - PR Newswire
Class Action Filed Against Kyverna Therapeutics, Inc. - GlobeNewswire
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - Morningstar
KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Final Deadline for the Kyverna Therapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsKYTX - PR Newswire
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: - GlobeNewswire
Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
KYVERNA THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc.KYTX - Business Wire
KYTX FINAL DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, - GlobeNewswire
DEADLINE ALERT for BOOM, KYTX, MQ, and SUI: The Law Offices - GlobeNewswire
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
2025-02-03 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Kyverna Therapeutics, Inc. to Contact the Firm Today! | NDAQ:KYTX | Press Release - Stockhouse Publishing
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 13.9% in January - MarketBeat
The Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineKYTX - PR Newswire
Shareholders that lost money on Kyverna Therapeutics, - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - GlobeNewswire
2025-02-02 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:KYTX | Press Release - Stockhouse Publishing
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - PR Newswire
KYTX DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, - GlobeNewswire
KYTX Shareholder Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors - GlobeNewswire
Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact Glancy Prongay & - EIN News
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before February 7, 2025 to Discuss Your RightsKYTX - PR Newswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ... - The Bakersfield Californian
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - GlobeNewswire Inc.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure ... - The Hastings Tribune
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna - GlobeNewswire
Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - The Eastern Progress Online
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - Victoria Advocate
Kyverna Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com
Kyverna Therapeutics Class Action: How to File a Claim Against the Firm - Lawyer Monthly Magazine
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - PR Newswire
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - The Malaysian Reserve
Kessler Topaz Meltzer & Check, LLP Announces KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. Securities Class Action Lawsuit - Business Wire
Kyverna Therapeutics Inc (KYTX) 재무 분석
Kyverna Therapeutics Inc (KYTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Kyverna Therapeutics Inc 주식 (KYTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
| Vida Ventures, LLC | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
253,136 |
5,568,992 |
252,553 |
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
3,163,868 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
910,000 |
20,020,000 |
4,126,119 |
| Northpond Ventures III GP, LLC | Former 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
450,000 |
1.09%
자본화:
|
볼륨(24시간):